Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil Consistency and Bridging Study (F.U.T.U.R.E.)
NCT00092482Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2002
- Primary completion
- Jun 2004
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC) and genital warts (5 arms), sponsored by Merck & Co. Primary endpoints: Immune responses (Geometric Mean Titers) and Tolerability (Adverse Events). Started Jun 2002; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)genital warts
Beyond the preview
Go deeper on NCT00092482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092482.